GLP-1s for PCOS: Can Microdosing Help You Manage Symptoms and Lose Weight?
GLP-1s for PCOS: Can Microdosing Help You Manage Symptoms and Lose Weight?

GLP-1s for PCOS: Can Microdosing Help You Manage Symptoms and Lose Weight?
For some people, losing body weight seems easy: eat less, move more. And plenty of healthcare professionals act like this simple formula should work for everyone. But if you’re living with polycystic ovarian syndrome (PCOS), then you know it’s not so simple.
Some research indicates that it’s possible for women with PCOS to lose about the same amount of weight as people without PCOS when they follow strict diet and exercise plans. But other studies demonstrate that people with PCOS tend to gain more weight over time than people without it, and that weight loss for someone with PCOS is a much more uphill battle.
Yet traditional healthcare often tells you to wait—to try lifestyle changes and 'wait and see'—even when your body is already signaling metabolic dysfunction. The gradual body weight gain, energy crashes after meals, difficulty managing cravings: these aren't minor inconveniences or signs you're not trying hard enough. They could be your metabolism asking for help, and at Found, we don’t believe you should have to wait until you're 'sick enough' to get care.
The tricky part? PCOS affects your metabolic health in ways that go far beyond what BMI can measure. The changes are often gradual—subtle weight gain, dysregulated appetite, bloating, fatigue—but they're real signals that your metabolism needs support. Healthcare has reduced metabolic health to a number on the scale, but true metabolic function exists beneath the surface. That's where microdosing can make a big difference: targeting the metabolic dysfunction caused by PCOS, regardless of whether you meet traditional BMI thresholds for treatment.
How does PCOS affect weight and insulin sensitivity?
PCOS can affect your body weight in several important ways. One of the biggest factors is insulin resistance, a key symptom of PCOS. Normally, insulin helps your body move sugar from the food you eat out of your bloodstream and into your cells, where it’s used for energy. But when your body becomes resistant to insulin, then it doesn’t always respond how it should. That means your system needs to produce more insulin to manage your blood glucose levels, and it also means that sugar stays in your bloodstream instead of getting used as fuel. Extra sugar in your blood gets stored as fat, resulting in weight gain.
PCOS also influences the hormones that regulate hunger and appetite. This means you might feel hungry or crave food more often, even when you’ve just eaten. As a result, people living with PCOS tend to eat slightly more calories on average than others, even when carefully following a diet and exercise plan. It’s not because you lack willpower; it’s because your hormones are sending signals that you’re still hungry and need to eat more. It’s a metabolic problem, not a character flaw. And the good news is, it’s treatable.
These metabolic changes don't happen overnight, and they don't always show up dramatically. But your body knows when something's off—and those signals deserve to be taken seriously.
How can GLP-1 medications help with PCOS symptoms?
Glucagon-like peptide-1 receptor agonists (GLP-1), are medications well known for supporting weight loss, but they may offer unique benefits for people with PCOS. GLP-1 agonists are medications that mimic natural hormones produced in the gut. These hormones help to regulate blood sugar, control appetite, and make you feel full after eating.
GLP-1s help your body manage glucose in a couple of key ways. First, they slow the release of glucagon, a protein that your cells convert into sugar. This helps prevent your body from raising blood sugar rapidly when you haven’t eaten. And second, GLP-1s encourage the pancreas to grow more beta cells, which produce insulin. More beta cells means your body can produce more insulin when it’s needed. The result is often more stable glucose levels and less sugar converted to fat.
GLP-1 meds can also help mitigate the extra hunger symptoms of PCOS. That’s because they help regulate a variety of hormones in both the gut and the brain that reduce appetite, stop cravings, and help you feel full. This means they make it easy to eat mindfully and to stop eating when you’re done.
Finally, GLP-1s can potentially improve other symptoms of PCOS. Early studies also show that they help reduce inflammation and improve cardiovascular health. And since they help with weight loss, they can even help potentially reduce the hormonal symptoms of PCOS, like period irregularity and fertility problems.
Is microdosing GLP-1s a better way to treat PCOS?
Typically, branded GLP-1s (Ozempic® (semaglutide), Mounjaro® (tirzepatide), Zepbound® (tirzepatide), Saxenda® (liraglutide)) are prescribed for people with obesity (a BMI over 30) or those who are overweight (a BMI over 25) and at least one related condition like diabetes or heart disease. Many of these meds are also approved to help manage blood sugar for people with type 2 diabetes.
But there’s a catch: the standard doses for these uses are relatively high, and they sometimes cause uncomfortable side effects like nausea, constipation, and diarrhea. In fact, as many as 50% of people prescribed these weight loss meds may quit within a year due to side effects.
And if you're living with PCOS, your symptoms may not fit into these boxes. PCOS is fundamentally a metabolic disorder, yet it's often dismissed or undiagnosed because symptoms can be subtle. You might notice small, unexplained weight gain over time, energy crashes after meals, difficulty managing cravings, or hormonal irregularities—all signs that your metabolism is already struggling. But healthcare has traditionally waited for you to be 'sick enough'—to cross arbitrary BMI thresholds or develop more severe metabolic disease—before offering treatment. Your doctor might tell you to try lifestyle changes and 'wait and see,' even though your body is already signaling it needs help.
That's where microdosing GLP-1 meds comes in. At Found, we define microdosing as preventive care for people with documented metabolic risks like PCOS—not as a generic protocol or cosmetic solution for otherwise healthy individuals. This approach means starting at a lower dose and increasing it gradually based on your body's response, which may help significantly reduce side effects. More importantly, it means intervening when your body signals it's time—treating metabolic dysfunction early, before it progresses. Instead of waiting for arbitrary thresholds to be crossed, you can take action now when prevention may be most effective.
How does the Found GLP-1 microdosing program work?
Curious if microdosing GLP-1s could help with your PCOS weight gain? At Found, we believe healthcare should listen when your body signals metabolic dysfunction—not dismiss your symptoms as normal or tell you to wait until you're worse. Our clinical team creates treatment plans designed specifically for you and your metabolic profile.
The first step of the process is our comprehensive metabolic assessment. Where applicable, you’ll get labs done at a location that’s convenient for you. You’ll also meet individually with one of our healthcare providers for a thorough one-on-one evaluation. You’ll discuss your health history, your symptoms, and your goals, and your provider will work with you to create a personalized treatment plan.
If medication is part of your plan, you’ll receive ongoing support, including regular check-ins, dose adjustments as needed, and guidance from your clinician. In addition, you’ll gain access to a dedicated coach and our supportive community to help you stay on track
When your symptoms are still subtle, traditional healthcare may tell you you're not sick enough to need treatment. But at Found, we validate what you already know about your body. Weight gain related to PCOS is a result of metabolic disorder that deserves treatment when your body signals dysfunction—not when arbitrary thresholds say you finally qualify. Your symptoms are real, and preventive intervention could make a profound difference in your long-term metabolic health.
Ready for healthcare that finally listens to what your body is telling you? Take our eligibility quiz today to discover if Found's personalized care is right for you.
Disclaimer
The content provided is for informational purposes only and should not be used as a basis for diagnosing or treating any health condition, or for determining actual costs incurred. Always follow your health care provider’s instructions to ensure safe and effective management of your health conditions. Found is not affiliated or endorsed by Novo Nordisk A/S., the owner of the registered trademarks Saxenda® and Ozempic®,, nor is it affiliated or endorsed by Eli Lilly & Co., the owner of the registered trademarks Zepbound® and Mounjaro®. Certain medications are only FDA-approved to treat conditions other than weight, but may be prescribed to help aid in weight loss. For key risk information by drug, visit the Found medication page. Compounded GLP-1s are not reviewed by the FDA for safety, efficacy, or quality, and are not approved to treat any specific condition. Potential benefits are based on early clinical studies, patient-reported outcomes, and provider observations. Individual results may vary. Any prescription medications referenced are always subject to individual provider evaluation and clinical eligibility.
Get the best of Found right in your inbox
Get started with Found
Ready to lose weight and live your healthiest life?
Sources
Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., & Madej, P. (2022). The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. International Journal of Molecular Sciences, 23(8), 4334. https://doi.org/10.3390/ijms23084334
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., Essawy, B. E., Jang, J., Loretelli, C., D’Addio, F., Berra, C., Nasr, M. B., Zuccotti, G., & Fiorina, P. (2022). The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacological Research, 182, 106320. https://doi.org/10.1016/j.phrs.2022.106320
Eldor, R., Avraham, N., Rosenberg, O., Shpigelman, M., Golan-Cohen, A., Cukierman-Yaffe, T., Merzon, E., & Buch, A. (2025). Gradual titration of semaglutide results in better treatment adherence and fewer adverse events: A randomized controlled Open-Label pilot study examining a 16-Week flexible titration regimen versus Label-Recommended 8-Week semaglutide titration regimen. Diabetes Care. https://doi.org/10.2337/dc25-0690
Hillman, S. C., & Dale, J. (2018). Polycystic ovarian syndrome: an under-recognised problem? British Journal of General Practice, 68(670), 244. https://doi.org/10.3399/bjgp18x696101
Hirschberg, A. L., Naessén, S., Stridsberg, M., Byström, B., & Holte, J. (2004). Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome. Gynecological Endocrinology, 19(2), 79–87. https://doi.org/10.1080/09513590400002300
Kataoka, J., Tassone, E., Misso, M., Joham, A., Stener-Victorin, E., Teede, H., & Moran, L. (2017). Weight Management Interventions in Women with and without PCOS: A Systematic Review. Nutrients, 9(9), 996. https://doi.org/10.3390/nu9090996
Lim, S., Smith, C. A., Costello, M. F., MacMillan, F., Moran, L., & Ee, C. (2019). Barriers and facilitators to weight management in overweight and obese women living in Australia with PCOS: a qualitative study. BMC Endocrine Disorders, 19(1). https://doi.org/10.1186/s12902-019-0434-8
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/nejmoa2307563
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H., Peters, T. M., & Eisenberg, M. J. (2025). Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation. The American Journal of Medicine. https://doi.org/10.1016/j.amjmed.2025.01.021
Moran, L., Ranasinha, S., Zoungas, S., McNaughton, S., Brown, W., & Teede, H. (2013). The contribution of diet, physical activity and sedentary behaviour to body mass index in women with and without polycystic ovary syndrome. Human Reproduction, 28(8), 2276–2283. https://doi.org/10.1093/humrep/det256
Purwar, A., & Nagpure, S. (2022). Insulin resistance in polycystic ovarian syndrome. Cureus. https://doi.org/10.7759/cureus.30351
Scragg, J., Hobson, A., Willis, L., Taylor, K. S., Dixon, S., & Jebb, S. A. (2024). Effect of weight loss interventions on the symptomatic burden and biomarkers of polycystic ovary syndrome. Annals of Internal Medicine. https://doi.org/10.7326/m23-3179
Teede, H. J., Joham, A. E., Paul, E., Moran, L. J., Loxton, D., Jolley, D., & Lombard, C. (2013). Longitudinal weight gain in women identified With polycystic ovary syndrome: Results of an observational study in young women. Obesity, 21(8), 1526–1532. https://doi.org/10.1002/oby.20213
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025). Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP‐1RA‐based weight‐loss therapies. Diabetes Obesity and Metabolism. https://doi.org/10.1111/dom.16364
Related articles





